Systematic review finds only three human BPC-157 studies, 30 participants total, very low certainty
A PRISMA-compliant systematic review identified three human studies of BPC-157 totalling 30 participants. All reported symptom improvement without treatment-related adverse events, but were judged poor quality with very low certainty of evidence.
Acta orthopaedica Belgica · 2026 · Review · n=30 · Human · Published October 16, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the study did
This is a systematic review of human studies, not an animal experiment: the authors pooled three studies covering 30 human participants in total. The review was described as PRISMA-compliant and prospectively registered with PROSPERO under registration number CRD420261406325.
The authors searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026, with eligibility covering quantitative and qualitative studies investigating BPC-157 for any indication in human participants. Methodological quality was assessed with the National Institutes of Health Quality Assessment Tool for Before-After Studies With No Control Group, certainty with GRADE, and findings were narratively synthesised following SWiM guidance.
What it reported
Three studies met the inclusion criteria. The authors describe a retrospective study of intra-articular BPC-157 injections for knee pain with 16 participants, a retrospective pilot study of intravesical BPC-157 for interstitial cystitis with 12 participants, and a prospective pilot study evaluating intravenous BPC-157 safety with 2 participants.
According to the abstract, all three studies reported symptom improvement in most participants without treatment-related adverse events. The authors also state that all three were judged to be of poor methodological quality, and that overall certainty of evidence was rated very low due to serious risk of bias, indirectness and imprecision.
The authors' stated conclusion is that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.
Reported dosing
The abstract does not report any doses, units, frequencies or treatment durations for the included studies. It names only the routes used in each included study — intra-articular injection for knee pain, intravesical administration for interstitial cystitis, and intravenous administration in the safety pilot — without stating the amounts given.
Limitations
The evidence base here is three studies and 30 people combined, with one of those studies enrolling just two participants. The quality appraisal tool the authors selected was designed for before-after studies with no control group, which reflects the uncontrolled nature of the included research.
The authors themselves rated all included studies as poor methodological quality and the overall certainty of evidence as very low, citing serious risk of bias, indirectness and imprecision. Findings were narratively synthesised rather than pooled statistically. A systematic review cannot be stronger than the studies it contains, and the abstract notes that evidence for BPC-157 is largely limited to animal models.
Regulatory context
BPC-157 is not an FDA-approved drug for any use. The abstract itself describes the compound as lacking regulatory approval for human use.
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The review was PRISMA-compliant and prospectively registered with PROSPERO.
“This PRISMA-compliant systematic review, prospectively registered with PROSPERO (CRD420261406325), aimed to evaluate the efficacy and safety of BPC-157 for orthopaedic and regenerative purposes in humans.”
Three studies totalling 30 human participants met the inclusion criteria, across knee pain, interstitial cystitis and an intravenous safety pilot.
“Three studies (n=30) met the inclusion criteria, consisting of a retrospective study of intra-articular BPC-157 injections for knee pain (n=16), a retrospective pilot study of intravesical BPC-157 for interstitial cystitis (n=12), and a prospective pilot study evaluating intravenous BPC-157 safety (n=2).”
All included studies reported symptom improvement in most participants and no treatment-related adverse events, but were judged poor quality.
“All studies reported symptom improvement in most participants without treatment-related adverse events, but were judged to be of poor methodological quality.”
Overall certainty of evidence was rated very low.
“Overall certainty of evidence was rated very low due to serious risk of bias, indirectness and imprecision.”
The authors conclude that clinical use outside regulated trials is not supported.
“Accordingly, BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.”
The authors describe the compound as popular among athletic populations despite lacking regulatory approval and an evidence base largely limited to animal models.
“Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide popular among athletic populations for musculoskeletal injury recovery, despite lacking regulatory approval for human use and evidence being largely limited to animal models.”
Common questions
How many human studies did the review find?
Three. The abstract states that three studies with a combined 30 participants met the inclusion criteria: a retrospective knee pain study (16 participants), a retrospective interstitial cystitis pilot (12 participants), and a prospective intravenous safety pilot (2 participants).
Were there control groups in the included studies?
The abstract does not describe control groups. Quality was assessed using the National Institutes of Health Quality Assessment Tool for Before-After Studies With No Control Group, and the authors rated the included studies as poor methodological quality.
Does the abstract state what doses were used?
No. The abstract names routes of administration — intra-articular, intravesical and intravenous — but reports no doses, units, frequencies or durations.
What did the authors conclude?
They concluded that overall certainty of evidence was very low due to serious risk of bias, indirectness and imprecision, and that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.
Source
- 1.Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety — Acta orthopaedica Belgica (2026)Reviewhumann=30PMID 42885452DOI 10.52628/92.3.15837